Can a new pill stop liver damage in hepatitis b patients?
NCT ID NCT07412236
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called hydronidone in people with liver scarring (fibrosis) from chronic hepatitis B. About 1,200 adults will take either hydronidone or a placebo, along with standard antiviral therapy, for up to 5 years. The goal is to see if hydronidone can prevent serious liver problems like cirrhosis, liver cancer, or the need for a transplant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can extra doses of an old drug reverse liver scarring?
- Can Weight-Loss surgery beat drugs for advanced liver damage?
- Navy beans take on fatty liver: a diet swap put to the test
- Could a cholesterol drug and a bile acid pill help reverse liver scarring?
- Stick-On ultrasound patch could spot liver damage without a specialist
- Food flavors on the breath may reveal hidden liver disease